Increased plasma concentrations of TGF-β, after hormone replacement therapy

Journal of Internal Medicine

Volumn 247, Issue 2, 2000, Pages 279-285

  Djurovic, Srdjan ^a   Os, I ^a   Hofstad, A E ^a   Abdelonoor, M ^a   Westheim, A ^a   Berg, K ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Hormone replacement therapy; Lp(a) lipoprotein; Oestradiol; TGF 1

Indexed keywords

ESTRADIOL; LIPOPROTEIN A; MEDROXYPROGESTERONE ACETATE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033956127     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00648.x     Document Type: Article

References (30)

1. 1 Massague J. The transforming growth factor beta family. Ann Rev Cell Biol 1990; 60: 597-641.
2. 2 Grainger DJ, Metcalfe JC. Transforming growth factor-β and cardiovascular protection. In: Rubanyi GM, Dzau VJ, eds. The Endothelium in Clinical Practice. New York: Marcel Dekker, Inc., 1997;203-43.
3. 3 Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis. Biol Rev 1995; 70: 571-96.
4. 4 Metcalfe JC, Grainger DJ. TGF-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans 1995; 23: 403-406.
5. 5 Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res 1997; 34: 404-10.
6. 6 Sartor BM, Sartor O, Flanders KC. Analogous tamoxifen and estrogen effects on transforming growth factor-betas 1 and 2 in the rat uterus. Reprod Toxicol 1995; 9: 225-31.
7. 7 Silbiger S, Lei J, Ziyadeh FN, Neugarten J. Estradiol reverses TGF-beta 1-stimulated type IV collagen gene transcription in murine mesangial cells. Am J Physiol 1998; 274: 1113-18.
8. 8 Kwan G, Neugarten J, Sherman M et al. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int 1996; 50: 1173-79.
9. 9 Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-62.
10. 10 Lawn RM, Pearle AD, Kunz LL et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996; 271: 31 367-71.
11. 11 Chauhan A, Williams NR, Metcalfe JC. Activation of transforming growth factor-β is inversely correlated with three major risk factors for coronary heart disease: lipoprotein(a), LDL-cholesterol and plasminogen activator inhibitor-1. Circulation 1994; 90: 1-623.
12. 12 Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360: 670-72.
13. 13 Berg K. A new serum type system in man - the Lp system. Acta Path Microbiol Scand 1963; 59: 369-82.
14. 14 Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52: 281-92.
15. 15 Os I, Hofstad AE, Brekke M et al. The EWA Study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. J Int Med 2000; in press.
16. 16 Magoffin DA, Hubert-Leslie D, Zachow RJ. Estradiol-17β, insulin-like growth factor-I, and luteinizing hormone inhibit secretion of transforming growth factor by rat ovarian theca-interstitial cells. Biol Reprod 1995; 53: 627-35.
17. 17 Ashcroft GS, Dodsworth J, Van Boxtel E et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta 1 levels. Nature Med 1997; 3: 1209-15.
18. 18 Selzman CH, Gaynor JS, Turner AS, Whitehill TA, Horwitz LD, Harken AH. Estrogen replacement inhibits intimal hyperplasia and the accumulation and effects of transforming growth factor beta I. J Surg Res 1998; 80: 380-5.
19. 19 Grainger DJ, Weissberg PL, Metcalfe JC. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J 1993; 294: 109-12.
20. 20 Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1995; 1: 1067-73.
21. 21 Grainger DJ, Kemp PR, Metcalfe JC et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995; 1: 74-9.
22. 22 Soma M, Fumagalli R, Paoletti R et al. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women (Letter). Lancet 1991; 1: 612.
23. 23 Farish E, Rolton HA, Barnes JE, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking noreshisterone. Br Med J 1991; 303: 694.
24. 24 Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) levels and lipids in postmenopausal women. Arterioscler Thromb 1994; 14: 275-81.
25. 25 Espeland MA, Marcovina SM, Miller V et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998; 97: 979-86.
26. 26 Hanggi W, Lippuner K, Riesen W. Jaeger P, Birkhauser MH. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997; 104: 708-17.
27. 27 Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996; 156: 1693-700.
28. 28 Soma MR, Osnago-Gadda I, Paoletti R et al. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993; 153: 1462-68.
29. 29 Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97: 1234-38.
30. 30 Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet 1994; 46: 57-62.